GSK to spend $110M upfront licensing Hutchmed's KRAS-EGFR cancer drug HMPL-A830, up to $1.295B total, pending antitrust clearance.
GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two…
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker…
Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed…
GSK made an all-cash bid to buy the small cancer-focused biotech company for $10.6 billion.
GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer…
The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui…
